CI Stock Analysis — Cigna
Sector: Healthcare
AI Verdict
Cigna trades at 8.9x next year's earnings while analysts expect nearly 29% EPS growth—this is cheap for the growth on offer if its scale moat keeps driving profit gains.
Competitive Moat
Cigna operates one of the largest pharmacy benefit management and health insurance platforms in the U.S., using scale to negotiate lower drug and care costs. Its integrated model and massive customer base create switching costs for employers and individuals, making it hard for new entrants to match its breadth or pricing power.
Summary
Cigna is trading at just 8.9x next year's earnings with analysts forecasting a 28.6% jump in EPS.
Where It Stands
The stock is down -3.38% over the past year, has an RSI of 41.6 (cooling, not oversold), and trades at 8.9x forward earnings versus the healthcare sector median of 22x.
Key Metrics
- RSI: 41.6 — Neutral
- Trailing P/E: 11.5x
- Forward P/E: 8.9x
- PEG Ratio: 0.42
- Earnings Growth: +0.3%
- Revenue Growth: +0.1%
- Market Cap: $73.3B
- Dividend Yield: 0.02%
- 1-Year Return: -3.38%
- 52-Week High: $315.47
- 52-Week Low: $239.51
Analyst Consensus
27 Buy · 7 Hold · 0 Sell (34 analysts)
Bull Case
With forward EPS growth expected at 28.6% and a forward P/E of 8.9x, you're paying a low price for substantial earnings growth if Cigna's scale-driven cost advantages hold.
Bear Case
If the P/E multiple reverts from 8.9x to the sector median of 22x, upside is huge, but if growth disappoints and the multiple drops to 7x, that would mean a further 21% downside from here.
Catalyst to Watch
Watch for upcoming earnings reports—if Cigna delivers on the 28.6% EPS growth forecast, the valuation gap could close quickly.